Amyloidosis and POEMS syndrome

Bibliography

• Comenzo RL. How I treat amyloidosis. Blood 2009;114:3147-57
   PubMed Web of Science ®Google Scholar
• Miyazaki D, Yazaki M, Gono T, AH amyloidosis associated with an immunoglobulin heavy chain variable region (VH1) fragment: a case report. Amyloid 2008;15:125-8
   PubMed Web of Science ®Google Scholar
• Baden EM, Sikkink LA, Ramirez-Alvarado M. Light chain amyloidosis – current findings and future prospects. Curr Protein Pept Sci 2009;10:500-8
   PubMed Web of Science ®Google Scholar
• Ionescu-Zanetti C, Khurana R, Gillespie JR, Monitoring the assembly of Ig light-chain amyloid fibrils by atomic force microscopy. Proc Natl Acad Sci U S A 1999;96:13175-9
   PubMed Web of Science ®Google Scholar
• Sorgjerd K, Klingstedt T, Lindgren M, Prefibrillar transthyretin oligomers and cold stored native tetrameric transthyretin are cytotoxic in cell culture. Biochem Biophys Res Commun 2008;377:1072-8
   PubMed Web of Science ®Google Scholar
• Sekijima Y, Kelly JW, Ikeda S. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr Pharm Des 2008;14:3219-30
   PubMed Web of Science ®Google Scholar
• van G II, van Rijswijk MH, Bijzet J, Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chain. Haematologica 2009;94:1094-100
   PubMed Web of Science ®Google Scholar
• Hazenberg BP, van Rijswijk MH, Lub-de Hooge MN, Diagnostic performance and prognostic value of extravascular retention of 123I-labeled serum amyloid P component in systemic amyloidosis. J Nucl Med 2007;48:865-72
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gertz MA, Greipp PR, A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997;336:1202-7
   PubMed Web of Science ®Google Scholar
• Skinner M, Anderson J, Simms R, Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 1996;100:290-8
   PubMed Web of Science ®Google Scholar
• Gertz MA, Lacy MQ, Lust JA, Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis. Haematologica 2008;93:1402-6
   PubMed Web of Science ®Google Scholar
• Palladini G, Merlini G. Current treatment of AL amyloidosis. Haematologica 2009;94:1044-8
   PubMed Web of Science ®Google Scholar
• Palladini G, Perfetti V, Obici L, Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem-cell transplantation. Blood 2004;103:2936-8
   PubMed Web of Science ®Google Scholar
• Palladini G, Russo P, Nuvolone M, Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood 2007;110:787-8
   PubMed Web of Science ®Google Scholar
• Palladini G, Russo P, Foli A, Treatment with oral melphalan and dexamethasone of an extended patient population with AL amyloidosis [abstract #3889]. Blood (ASH Annual Meeting Abstracts) 2009;114:3889
   Google Scholar
• Sanchorawala V, Wright DG, Seldin DC, Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis. Br J Haematol 2002;117:886-9
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Seldin DC, Sloan JM, Oral cyclic melphalan and dexamethasone in the treatment of patients with AL amyloidosis; ineligible for high-dose melphalan and stem-cell transplantation [abstract#1883]. Blood (ASH Annual Meeting Abstracts) 2009;114:1883
   Google Scholar
• Comenzo RL, Vosburgh E, Simms RW, Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood 1996;88:2801-6
   PubMed Web of Science ®Google Scholar
• Comenzo RL, Vosburgh E, Falk RH, Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998;91:3662-70
   PubMed Web of Science ®Google Scholar
• Seldin DC, Anderson JJ, Sanchorawala V, Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem-cell transplantation. Blood 2004;104:1888-93
   PubMed Web of Science ®Google Scholar
• Seldin DC, Anderson JJ, Skinner M, Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem-cell transplantation in patients over age 65. Blood 2006;108:3945-7
   PubMed Web of Science ®Google Scholar
• Gertz MA, Lacy MQ, Dispenzieri A, Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Haematologica 2007;92:1415-8
   PubMed Web of Science ®Google Scholar
• Leung N, Slezak JM, Bergstralh EJ, Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem-cell transplantation. Am J Kidney Dis 2005;45:102-11
   PubMed Web of Science ®Google Scholar
• Porrata LF, Gertz MA, Litzow MR, Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem-cell transplantation for patients with primary systemic amyloidosis. Clin Cancer Res 2005;11:1210-8
   PubMed Web of Science ®Google Scholar
• Leung N, Leung TR, Cha SS, Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem-cell transplantation in AL amyloidosis patients. Blood 2005;106:3353-7
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Lacy MQ, Katzmann JA, Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem-cell transplantation. Blood 2006;107:3378-83
   PubMed Web of Science ®Google Scholar
• Comenzo RL, Gertz MA. Autologous stem-cell transplantation for primary systemic amyloidosis. Blood 2002;99:4276-82
   PubMed Web of Science ®Google Scholar
• Goodman HJ, Gillmore JD, Lachmann HJ, Outcome of autologous stem-cell transplantation for AL amyloidosis in the UK. Br J Haematol 2006;134:417-25
   PubMed Web of Science ®Google Scholar
• Gertz MA, Lacy MQ, Dispenzieri A, Stem-cell transplantation for the management of primary systemic amyloidosis. Am J Med 2002;113:549-55
   PubMed Web of Science ®Google Scholar
• Saba N, Sutton D, Ross H, High treatment-related mortality in cardiac amyloid patients undergoing autologous stem-cell transplant. Bone Marrow Transplant 1999;24:853-5
   PubMed Web of Science ®Google Scholar
• Kumar S, Dispenzieri A, Lacy MQ, High incidence of gastrointestinal tract bleeding after autologous stem-cell transplant for primary systemic amyloidosis. Bone Marrow Transplant 2001;28:381-5
   PubMed Web of Science ®Google Scholar
• Gertz MA, Lacy MQ, Dispenzieri A, Risk-adjusted manipulation of melphalan dose before stem-cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 2004;34:1025-31
   PubMed Web of Science ®Google Scholar
• Vesole DH, Perez WS, Akasheh M, High-dose therapy and autologous hematopoietic stem-cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study. Mayo Clin Proc 2006;81:880-8
   PubMed Web of Science ®Google Scholar
• Jaccard A, Moreau P, Leblond V, High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007;357:1083-93
   PubMed Web of Science ®Google Scholar
• Kumar S, Dispenzieri A, Gertz MA. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2008;358:91, 92,93
   PubMed Web of Science ®Google Scholar
• Comenzo RL. Systemic immunoglobulin light-chain amyloidosis. Clin Lymphoma Myeloma 2006;7:182-5
   PubMedGoogle Scholar
• Lebovic D, Hoffman J, Levine BM, Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem-cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol 2008;143:369-73
   PubMed Web of Science ®Google Scholar
• Schonland S, Hegenbart U, Benner A, Prospective Phase II study using dexamethasone induction therapy and high-dose melphalan chemotherapy followed by autologous stem-cell transplantation in 30 patients with systemic AL amyloidosis [abstract #3401]. Blood (ASH Annual Meeting Abstracts) 2009;114:3401
   Google Scholar
• Madan S, Kumar S, Dispenzieri A, Outcomes with high dose therapy and peripheral blood stem-cell transplantation for light chain (AL) amyloidosis with cardiac involvement [abstract #534]. Blood (ASH Annual Meeting Abstracts) 2009;114:534
   Google Scholar
• Seldin DC, Choufani EB, Dember LM, Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin Lymphoma 2003;3:241-6
   PubMedGoogle Scholar
• Dispenzieri A, Lacy MQ, Rajkumar SV, Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid 2003;10:257-61
   PubMed Web of Science ®Google Scholar
• Palladini G, Perfetti V, Perlini S, The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 2005;105:2949-51
   PubMed Web of Science ®Google Scholar
• Palladini G, Russo P, Lavatelli F, Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Ann Hematol 2009;88:347-50
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Wright DG, Rosenzweig M, Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a Phase 2 trial. Blood 2007;109:492-6
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Lacy MQ, Zeldenrust SR, The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007;109:465-70
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Lacy M, Zeldenrust SR, long term follow-up of patients with immunoglobulin light chain amyloidosis treated with lenalidomide and dexamethasone [abstract #1737]. Blood (ASH Annual Meeting Abstracts) 2008;112:1737
   Google Scholar
• Moreau P, Jaccard A, Benboubker L, Lenalidomide in combination with melphalan and dexamethasone in patients with newly-diagnosed light-chain (AL)-amyloidosis: a multicenter Phase I/II dose escalation study [abstract #427]. Blood (ASH Annual Meeting Abstracts) 2009;112:427
   Google Scholar
• Sloan JM, Sanchorawala V, Girnius S, Melphalan, lenalidomide, and dexamethasone combination therapy in patients with AL amyloidosis [abstract #1859]. Blood (ASH Annual Meeting Abstracts) 2009;114:1859
   Google Scholar
• Kastritis E, Roussou M, Migkou M, A Phase I/II study of lenalidomide (R) with low dose dexamethasone (d) and cyclophosphamide (C) for patients with primary systemic (AL) amyloidosis [abstract #428]. Blood (ASH Annual Meeting Abstracts) 2009;114:428
   Google Scholar
• Palladini G, Russo P, Bragotti LZ, A Phase II trial of cyclophosphamide, lenalidomide and dexamethasone (CLD) in previously treated patients with AL amyloidosis [abstract #2863]. Blood (ASH Annual Meeting Abstracts) 2009;114:2863
   Google Scholar
• Kumar S, Hayman SR, Buadi F, A Phase II trial of lenalidomide, cyclophosphamide and dexamethasone (RCD) in patients with light chain amyloidosis [abstract #3853]. Blood (ASH Annual Meeting Abstracts) 2009;114:3853
   Google Scholar
• Sterz J, von Metzler I, Hahne JC, The potential of proteasome inhibitors in cancer therapy. Expert Opin Investig Drugs 2008;17:879-95
   PubMed Web of Science ®Google Scholar
• Sitia R, Palladini G, Merlini G. Bortezomib in the treatment of AL amyloidosis: targeted therapy? Haematologica 2007;92:1302-7
   PubMed Web of Science ®Google Scholar
• Wechalekar AD, Lachmann HJ, Offer M, Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 2008;93:295-8
   PubMed Web of Science ®Google Scholar
• Reece DE, Sanchorawala V, Hegenbart U, Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a Phase 1 dose-escalation study. Blood 2009;114:1489-97
   PubMed Web of Science ®Google Scholar
• Kastritis E, Anagnostopoulos A, Roussou M, Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 2007;92:1351-8
   PubMed Web of Science ®Google Scholar
• Lamm W, Willenbacher W, Zojer N, efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis [abstract #2871]. Blood (ASH Annual Meeting Abstracts) 2009;114:2871
   Google Scholar
• Landau H, Hassoun H, Cohen AD, Adjuvant bortezomib and dexamethasone following risk-adapted melphalan and stem-cell transplant in systemic light-chain amyloidosis (AL): a Phase II study. Blood ASH Annual Meeting Abstracts 2009;114:533
   Web of Science ®Google Scholar
• Kastritis E, Wechalekar AD, Dimopoulos MA, Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 2010;28(6):1031-7 [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Gertz MA, Hayman SR, A pilot study of pomalidomide and dexamethasone in previously treated light chain amyloidosis patients [abstract #3854]. Blood (ASH Annual Meeting Abstracts) 2009;114:3854
   Google Scholar
• Dispenzieri A. POEMS syndrome. Blood Rev 2007;21:285-99
   PubMed Web of Science ®Google Scholar
• Martin S, Labauge P, Jouanel P, Restricted use of Vlambda genes in POEMS syndrome. Haematologica 2004;89:ECR02
   PubMedGoogle Scholar
• Nakaseko C, Abe D, Takeuchi M, Restricted oligo-clonal usage of monoclonal immunoglobulin {lambda} light chain germline in POEMS syndrome. ASH Annual Meeting Abstracts 2007;110:2483
   Google Scholar
• Aravamudan B, Tong C, Lacy MQ, Immunoglobulin variable light chain restriction, cytokine expression and plasma cell-stromal cell interactions in POEMS syndrome patients. ASH Annual Meeting Abstracts 2008;112:2744
   Google Scholar
• Bryce AH, Ketterling RP, Gertz MA, Cytogenetic analysis using multiple myeloma targets in POEMS syndrome. Proceedings of American Society of Oncology Meeting, Chicago, IL; 2007
   Google Scholar
• Kuwabara S, Dispenzieri A, Arimura K, Misawa S. Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. Cochrane Database Syst Rev 2008:CD006828
   Google Scholar
• Allam JS, Kennedy CC, Aksamit TR, Dispenzieri A. Pulmonary manifestations in patients with POEMS syndrome: a retrospective review of 137 patients. Chest 2008;133:969-74
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Kyle RA, Lacy MQ, POEMS syndrome: definitions and long-term outcome. Blood 2003;101:2496-506
   PubMed Web of Science ®Google Scholar
• Lesprit P, Authier FJ, Gherardi R, Acute arterial obliteration: a new feature of the POEMS syndrome? Medicine (Baltimore) 1996;75:226-32
   PubMed Web of Science ®Google Scholar
• Dupont SA, Dispenzieri A, Mauermann ML, Cerebral infarction in POEMS syndrome: incidence, risk factors, and imaging characteristics. Neurology 2009;73:1308-12
   PubMed Web of Science ®Google Scholar
• Sanada S, Ookawara S, Karube H, Marked recovery of severe renal lesions in POEMS syndrome with high-dose melphalan therapy supported by autologous blood stem-cell transplantation. Am J Kidney Dis 2006;47:672-9
   PubMed Web of Science ®Google Scholar
• Gandhi GY, Basu R, Dispenzieri A, Endocrinopathy in POEMS syndrome: the Mayo Clinic experience. Mayo Clin Proc 2007;82:836-42
   PubMed Web of Science ®Google Scholar
• Hughes RA, Bouche P, Cornblath DR, European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2006;13(4):326-32
   PubMed Web of Science ®Google Scholar
• Sung JY, Kuwabara S, Ogawara K, Patterns of nerve conduction abnormalities in POEMS syndrome. Muscle Nerve 2002;26:189-93
   PubMed Web of Science ®Google Scholar
• Min JH, Hong YH, Lee KW. Electrophysiological features of patients with POEMS syndrome. Clin Neurophysiol 2005;116:965-8
   PubMed Web of Science ®Google Scholar
• Lesprit P, Godeau B, Authier FJ, Pulmonary hypertension in POEMS syndrome: a new feature mediated by cytokines. Am J Respir Crit Care Med 1998;157:907-11
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E, Terenghi F, Giannotta C, Serum VEGF levels in POEMS syndrome and in immune-mediated neuropathies. Neurology 2009;72:1024-6
   PubMed Web of Science ®Google Scholar
• Soubrier MJ, Dubost JJ, Sauvezie BJ. POEMS syndrome: a study of 25 cases and a review of the literature. French Study Group on POEMS syndrome. Am J Med 1994;97:543-53
   PubMed Web of Science ®Google Scholar
• Nakano A, Mitsui T, Endo I, Solitary plasmacytoma with VEGF overproduction: report of a patient with polyneuropathy. Neurology 2001;56:818-9
   PubMed Web of Science ®Google Scholar
• Mineta M, Hatori M, Sano H, Recurrent Crow-Fukase syndrome associated with increased serum levels of vascular endothelial growth factor: a case report and review of the literature. Tohoku J Exp Med 2006;210:269-77
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Lacy MQ, Hayman SR, Peripheral blood stem-cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome. Eur J Haematol 2008;80:397-406
   PubMed Web of Science ®Google Scholar
• Kuwabara S, Misawa S, Kanai K, Neurologic improvement after peripheral blood stem-cell transplantation in POEMS syndrome. Neurology 2008;71:1691-5
   PubMed Web of Science ®Google Scholar
• Sinisalo M, Hietaharju A, Sauranen J, Wirta O. Thalidomide in POEMS syndrome: case report. Am J Hematol 2004;76:66-8
   PubMed Web of Science ®Google Scholar
• Kim SY, Lee SA, Ryoo HM, Thalidomide for POEMS syndrome. Ann Hematol 2006;85:545-6
   PubMed Web of Science ®Google Scholar
• Kuwabara S, Misawa S, Kanai K, Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome. J Neurol Neurosurg Psychiatry 2008;79:1255-7
   PubMed Web of Science ®Google Scholar
• Ohwada C, Nakaseko C, Sakai S, Successful combination treatment with bevacizumab, thalidomide and autologous PBSC for severe POEMS syndrome. Bone Marrow Transplant 2009;43:739-40
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Klein CJ, Mauermann ML. Lenalidomide therapy in a patient with POEMS syndrome. Blood 2007;110:1075-6
   PubMed Web of Science ®Google Scholar
• Jaccard A, Abraham J, Recher C, Lenalidomide therapy in nine patients with POEMS syndrome. ASH Annual Meeting Abstracts 2009;114:3872
   Google Scholar
• Tang X, Shi X, Sun A, Successful bortezomib-based treatment in POEMS syndrome. Eur J Haematol 2009;83:609-10
   PubMed Web of Science ®Google Scholar
• Kaygusuz I, Tezcan H, Cetiner M, Bortezomib: a new therapeutic option for POEMS syndrome. Eur J Haematol 2010;84:175-7
   PubMed Web of Science ®Google Scholar
• Badros A, Porter N, Zimrin A. Bevacizumab therapy for POEMS syndrome. Blood 2005;106:1135
   PubMed Web of Science ®Google Scholar
• Straume O, Bergheim J, Ernst P. Bevacizumab therapy for POEMS syndrome. Blood 2006;107:4972-3, 4974
   PubMed Web of Science ®Google Scholar
• Dietrich PY, Duchosal MA. Bevacizumab therapy before autologous stem-cell transplantation for POEMS syndrome. Ann Oncol 2008;19:595
   PubMed Web of Science ®Google Scholar
• Samaras P, Bauer S, Stenner-Liewen F, Treatment of POEMS syndrome with bevacizumab. Haematologica 2007;92:1438-9
   PubMed Web of Science ®Google Scholar
• Straume O, Bergheim J, Ernst P, Bevacizumab therapy for POEMS syndrome. Blood 2006;107:4972-4
   PubMed Web of Science ®Google Scholar
• Available from: http://msmart.org/msmart_mar09_002.htm
   Google Scholar
• Kanai K, Kuwabara S, Misawa S, Hattori T. Failure of treatment with anti-VEGF monoclonal antibody for long-standing POEMS syndrome. Intern Med 2007;46:311-3
   PubMed Web of Science ®Google Scholar